The efficacy and safety of low-molecular-weight heparins for venous thromboembolism prophylaxis in abdominal or pelvic cancer surgery: A systematic review and network meta-analysis of randomized controlled trials

被引:0
|
作者
Liu, Kun [1 ]
Hu, Can [1 ]
Zhou, Ling-yun [1 ]
Tang, Zhi-yao [1 ]
Wu, Yi-feng [1 ]
Huang, Yu-jie [1 ]
Zuo, Xiao-cong [1 ,2 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Dept Pharm, Changsha 410013, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp 3, Ctr Clin Pharmacol, Changsha 410013, Hunan, Peoples R China
关键词
Low-molecular-weight heparins; Cancer; Abdominal or pelvic cancer surgery; Venous thromboembolism; Hemorrhage; Network meta-analysis; PNEUMATIC COMPRESSION; PREVENTION; ENOXAPARIN; SURVIVAL; DEFINITION; GUIDELINES; MANAGEMENT; BREAST;
D O I
10.1016/j.thromres.2025.109294
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Low-molecular-weight heparins (LMWHs) have been widely used for thromboprophylaxis in postoperative patients with abdominal or pelvic cancer. However, evidence regarding the optimal type of LMWHs remains limited. Objective: This study aims to evaluate the efficacy and safety of different types of LMWHs in patients undergoing abdominal or pelvic cancer surgery through a network meta-analysis of randomized controlled trials (RCTs). Methods: The network meta-analysis was guided by the PRISMA guidelines. The primary outcomes included venous thromboembolism (VTE), major bleeding, and all-cause death. Results were summarized with relative ratios (RR) and 95 % confidence intervals (CIs). The surface under the cumulative ranking curve (SUCRA) was calculated to assess the performance of various LMWHs. Results: A total of 19 RCTs involving 6318 patients were identified. Compared to non-LMWH, LMWHs significantly reduced the risk of VTE [RR 0.57, (95 % CI 0.41-0.81)], DVT [RR 0.56, (95 % CI 0.39-0.81)], and PE [RR 0.26, (95 % CI 0.10-0.66)], without increasing the risk of all-cause death [RR 0.67, (95 % CI 0.39-1.14)], major bleeding [RR 1.51, (95 % CI 0.82-2.77)], minor bleeding [RR 1.23, (95 % CI 0.84-1.80)], all bleeding [RR 1.35, (95 % CI 0.98-1.84)], or thrombocytopenia [RR 0.41, (95 % CI 0.13-1.31)]. Notably, no significant differences in efficacy and safety were observed among different types of LMWHs, with parnaparin (SUCRA 86.3), dalteparin (SUCRA 74.5), and certoparin (SUCRA 88.5) ranking highest in the prevention of VTE, major bleeding, and allcause death, respectively. Conclusion: LMWHs are efficacious options for thromboprophylaxis in patients undergoing abdominal or pelvic cancer surgery, without increasing the risk of major bleeding or all-cause death. However, no significant differences were observed in efficacy and safety among different types of LMWHs used in this context.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis
    Tarinee Rungjirajittranon
    Weerapat Owattanapanich
    Yingyong Chinthammitr
    Theera Ruchutrakool
    Bundarika Suwanawiboon
    Thrombosis Journal, 20
  • [22] Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials
    Frere, Corinne
    Farge, Dominique
    Schrag, Deborah
    Prata, Pedro H.
    Connors, Jean M.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [23] Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis
    Wu, Shuyi
    Lv, Meina
    Chen, Jiana
    Jiang, Shaojun
    Chen, Mingrong
    Fang, Zongwei
    Zeng, Zhiwei
    Qian, Jiafen
    Xu, Wenlin
    Guan, Chengfu
    Zhang, Jinhua
    SUPPORTIVE CARE IN CANCER, 2022, 30 (12) : 10407 - 10420
  • [24] Efficacy and Safety of Pharmacoprophylaxis for Venous Thromboembolism in Patients Undergoing Bariatric Surgery: a Systematic Review and Meta-analysis
    Zhao, Ying
    Ye, Zhikang
    Lin, Jianrui
    Zhang, Zhiqi
    Tian, Peirong
    Zhang, Zhongtao
    Zhang, Peng
    Cui, Xiangli
    OBESITY SURGERY, 2022, 32 (05) : 1701 - 1718
  • [25] The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials
    Sanford, D.
    Naidu, A.
    Alizadeh, N.
    Lazo-Langner, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (07) : 1076 - 1085
  • [26] Prophylaxis and treatment of venous thromboembolism in cancer patients. Clinical value of low-molecular-weight heparins
    Kreher, S.
    Riess, H.
    INTERNIST, 2014, 55 (04): : 448 - +
  • [27] Prevention of Venous Thromboembolism in Major Orthopedic Surgery: Bayesian Network Meta-Analysis of 21 Randomized Trials Evaluating Unfractionated Heparins, Low-Molecular Weight Heparins, and New Oral Anticoagulants
    Messori, Andrea
    Trippoli, Sabrina
    Maratea, Dario
    Fadda, Valeria
    Marinai, Claudio
    INTERNATIONAL CARDIOVASCULAR RESEARCH JOURNAL, 2015, 9 (04) : 238 - 242
  • [28] Safety and efficacy of low-molecular-weight heparin in patients with acute venous thromboembolism postthrombolytic therapy as compared to unfractionated heparin: A systematic review and meta-analysis
    Mansory, Eman M.
    Al-Kathiry, Maha S.
    Alzahrani, Abdulelah
    IRAQI JOURNAL OF HEMATOLOGY, 2024, 13 (02) : 238 - 250
  • [29] Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: A systematic review and meta-analysis
    Ikesaka, Rick
    Delluc, Aurelien
    Le Gal, Gregoire
    Carrier, Marc
    THROMBOSIS RESEARCH, 2014, 133 (04) : 682 - 687
  • [30] Effectiveness and safety of rivaroxaban or low-molecular-weight heparin in non-major orthopedic surgery: a meta-analysis of randomized controlled trials
    Zhu, Lemei
    Zhu, Bohua
    Bing, Pingping
    Qi, Mingxu
    He, Binsheng
    JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, 2024, 19 (01):